scholarly journals Alectinib Together with Intracranial Therapies Improved Survival Outcomes in Untreated ALK-Positive Patients with Non-Small-Cell Lung Cancer and Symptomatic and Synchronic Brain Metastases: A Retrospective Study

2021 ◽  
Vol Volume 14 ◽  
pp. 5533-5542
Author(s):  
Qiang Yin ◽  
Peng Li ◽  
Peng Wang ◽  
Zhen Zhang ◽  
Qun Liu ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Retrospective Study ◽  
Brain Metastases ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Survival Outcomes ◽  
Small Cell Lung ◽  
Alk Positive

Systemic chemotherapy after cranial irradiation in patients with brain metastases from non-small cell lung cancer: A retrospective study

Lung Cancer ◽  
2009 ◽  
Vol 63 (3) ◽  
pp. 405-409 ◽  
Author(s):  
Jung Han Kim ◽  
Hyeong Su Kim ◽  
Jung Hye Kwon ◽  
Sarah Park ◽  
Ho Young Kim ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Retrospective Study ◽  
Brain Metastases ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Systemic Chemotherapy ◽  
Cranial Irradiation ◽  
Small Cell ◽  
Small Cell Lung

P45.11 Co-occurring CDKN2A/B Alteration Is Associated With Worse Survival Outcomes in Advanced ALK-Positive Non-Small Cell Lung Cancer

2021 ◽  
Vol 16 (10) ◽  
pp. S1090
Author(s):  
L. Lara-Mejía ◽  
D. Heredia ◽  
N. Hernández-Pedro ◽  
E. Varela-Santoyo ◽  
G. Cruz-Rico ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Survival Outcomes ◽  
Small Cell Lung ◽  
Alk Positive

Retrospective study on bevacizumab in the treatment of non-small cell lung cancer with brain metastases

2019 ◽  
Vol 25 (2) ◽  
pp. 267-273 ◽  
Author(s):  
Zhen Wang ◽  
Jin-Ji Yang ◽  
Hai-Yan Tu ◽  
Hong-Hong Yan ◽  
Yi-Long Wu
Keyword(s):  
Lung Cancer ◽  
Retrospective Study ◽  
Brain Metastases ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Small Cell Lung

scholarly journals Lung-molGPA Index Predicts Survival Outcomes of Non-Small-Cell Lung Cancer Patients with Synchronous or Metachronous Brain Metastases

2020 ◽  
Vol Volume 13 ◽  
pp. 8837-8844 ◽  
Author(s):  
Kaiyan Chen ◽  
Fanrong Zhang ◽  
Yun Fan ◽  
Guoping Cheng
Keyword(s):  
Lung Cancer ◽  
Brain Metastases ◽  
Small Cell Lung Cancer ◽  
Cancer Patients ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Survival Outcomes ◽  
Small Cell Lung ◽  
Lung Cancer Patients

Rapid Flare of Brain Metastases in ALK-Positive Non-Small Cell Lung Cancer after Stopping Crizotinib

2017 ◽  
Vol 05 (03) ◽  
Author(s):  
Juengsamarn J ◽  
Sirachainan E ◽  
Reungwetwattana T
Keyword(s):  
Lung Cancer ◽  
Brain Metastases ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Small Cell Lung ◽  
Alk Positive

Survival of crizotinib continuation plus brain radiotherapy among ALK positive non-small cell lung cancer (NSCLC) patients with brain metastases during crizotinib treatment.

2018 ◽  
Vol 36 (15_suppl) ◽  
pp. e21142-e21142
Author(s):  
Guangjian Yang ◽  
Di Ma ◽  
Puyuan Xing ◽  
Haiyan Xu ◽  
Li Junling ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Brain Metastases ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Small Cell Lung ◽  
Brain Radiotherapy ◽  
Alk Positive ◽  
Nsclc Patients

scholarly journals Economic impact of preventing brain metastases with alectinib in ALK-positive non-small cell lung cancer

Lung Cancer ◽  
2018 ◽  
Vol 119 ◽  
pp. 103-111 ◽  
Author(s):  
C. Burudpakdee ◽  
W. Wong ◽  
A. Seetasith ◽  
F.A. Corvino ◽  
W. Yeh ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Brain Metastases ◽  
Small Cell Lung Cancer ◽  
Economic Impact ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Small Cell Lung ◽  
Alk Positive

Exploratory Analysis of Brigatinib Activity in Patients With Anaplastic Lymphoma Kinase-Positive Non–Small-Cell Lung Cancer and Brain Metastases in Two Clinical Trials

2018 ◽  
Vol 36 (26) ◽  
pp. 2693-2701 ◽  
Author(s):  
D. Ross Camidge ◽  
Dong-Wan Kim ◽  
Marcello Tiseo ◽  
Corey J. Langer ◽  
Myung-Ju Ahn ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Brain Metastases ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Anaplastic Lymphoma Kinase ◽  
Small Cell ◽  
Small Cell Lung ◽  
Once Daily ◽  
Anaplastic Lymphoma ◽  
Alk Positive

Purpose In patients with crizotinib-treated, anaplastic lymphoma kinase gene ( ALK)-rearranged non–small-cell lung cancer (ALK-positive NSCLC), initial disease progression often occurs in the CNS. We evaluated brigatinib, a next-generation ALK inhibitor, in patients with ALK-positive NSCLC with brain metastases. Patients and Methods Patients with ALK-positive NSCLC received brigatinib (90 to 240 mg total daily) in a phase I/II trial (phI/II; ClinicalTrials.gov identifier: NCT01449461) and in the subsequent randomized phase II trial ALTA (ALK in Lung Cancer Trial of AP26113; ClinicalTrials.gov identifier: NCT02094573; patients in arm A received 90 mg once daily; patients in arm B received 180 mg once daily with 7-day lead-in at 90 mg). Primary end points (systemic objective response rates [ORRs]) were previously reported. Independent review committees assessed intracranial efficacy in patients with baseline brain metastases. Results Most patients with ALK-positive NSCLC had baseline brain metastases (50 of 79 [63%], phI/II; 80 of 112 [71%] and 73 of 110 [66%] in ALTA arms A and B, respectively), many of whom had no prior brain radiotherapy (23 of 50 [46%], phI/II; 32 of 80 [40%], ALTA arm A; 30 of 73 [41%], arm B). All patients, except four in phI/II, had received crizotinib. Among patients with measurable (≥ 10 mm) brain metastases, confirmed intracranial ORR was 53% (eight of 15; 95% CI, 27% to 79%) in phI/II, 46% (12 of 26; 95% CI, 27% to 67%) in ALTA arm A, and 67% (12 of 18; 95% CI, 41% to 87%) in arm B. Intracranial ORRs were similar in subsets without prior radiation or progression postradiation. Among patients with any baseline brain metastases, median intracranial progression-free survival (iPFS) was 14.6 months (95% CI, 12.7 to 36.8 months), phI/II; 15.6 months (95% CI, 9.0 to 18.3 months), ALTA arm A; 18.4 months (95% CI, 12.8 months to not reached), ALTA arm B. Conclusion Brigatinib yielded substantial intracranial responses and durable iPFS in ALK-positive, crizotinib-treated NSCLC, with highest iPFS in patients receiving 180 mg once daily (with lead-in).

Sign in / Sign up

Export Citation Format

Share Document